NOVOSIBIRSK, August 17. /TASS/. The Vector State Research Center of Virology and Biotechnology in Novosibirsk has started the second phase of clinical studies of the vaccine against the novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback